MITIGATE

MITIGATE_rgbUnder the Project Management of EIBIR and the Coordination of Professor Stefan Schönberg at Ruprecht-Karls-University Heidelberg, Germany, the interdisciplinary consortium of the project proposal “MITIGATE: Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours” comprises ten partners from Austria, France, Germany, and Italy. MITIGATE will run from October 2013 – 2017, and receives €4.5 M in co-funding from the European Commission under the 7th Framework Programme.

Background 
Gastrointestinal stromal tumour (GIST) is a rare disease and frequently affects young patients with high potential for metastasising, which often results in a short life expectancy of less than 3 years. Currently there is only one class of effective medications, the tyrosine kinase inhibitors (TKI), for systemic GIST therapy and often the tumours develop drug resistance after a few years. No molecular imaging technologies indicating drug resistance, early therapeutic response or disease progression are clinically available. Furthermore,  effective targeted agents with other mechanisms of action such as endoradiopharmaceuticals are not designed for treatment of GIST and alternative minimally-invasive treatment options for metastatic disease are not well explored nor has the clinical value of their combined use been established. This leaves GIST patients with very  limited treatment options.

Objective
The overall objective of the MITIGATE project is to develop and validate an integrated closed-loop process to effectively treat metastatic GIST patients resistant to the currently available class of medication, the TKI. This envisaged personalised treatment concept combines innovative strategies for biopsy, inline tissue analysis, molecular tumour characterisation, theranostics by imaging technologies (PET and MRI) and companion radiopharmaceuticals followed by the assessment of biodistribution, dose calculation and measurement of therapeutic effectiveness. In addition, synergistic concepts of minimally-invasive treatment will be applied. EIBIR will be in charge of the management of the consortium and also lead the work package on dissemination and exploitation.

The project website is currently being developed and will be available soon under www.mitigate-project.eu